Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
85 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Fragile X Syndrome - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Fragile X Syndrome - Pipeline Review, H2 2014', provides an overview of the Fragile X Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fragile X Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fragile X Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Fragile X Syndrome Overview 8 Therapeutics Development 9 Pipeline Products for Fragile X Syndrome - Overview 9 Pipeline Products for Fragile X Syndrome - Comparative Analysis 10 Fragile X Syndrome - Therapeutics under Development by Companies 11 Fragile X Syndrome - Therapeutics under Investigation by Universities/Institutes 13 Fragile X Syndrome - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Fragile X Syndrome - Products under Development by Companies 17 Fragile X Syndrome - Products under Investigation by Universities/Institutes 18 Fragile X Syndrome - Companies Involved in Therapeutics Development 19 Alcobra Ltd 19 Confluence Pharmaceuticals LLC 20 Cortex Pharmaceuticals, Inc. 21 F. Hoffmann-La Roche Ltd. 22 Hua Medicine Ltd. 23 Marinus Pharmaceuticals, Inc. 24 MI.TO. Technology S.r.L. 25 Neuren Pharmaceuticals Limited 26 Nexgenix Pharmaceuticals, LLC 27 Paratek Pharmaceuticals, Inc. 28 Selvita SA 29 Fragile X Syndrome - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 acamprosate calcium - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 basimglurant - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 CX-929 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Drugs to Inhibit mGluR5 for Fragile X Syndrome - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 ganaxolone - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Metadoxine ER - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 minocycline - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 NNZ-2566 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 NNZ-2591 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 PTKMS-01 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 SEL-203 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecule for FXTAS - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecule to Activate Epsilon PKC for Fragile X Syndrome - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecules to Agonize 5-HT7 for Fragile X Syndrome - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small molecules to Antagonize mGLUR5 for Fragile X Syndrome - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Small Molecules to Inhibit Pak for Genetic Disorders - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 SRT-278 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Fragile X Syndrome - Recent Pipeline Updates 62 Fragile X Syndrome - Dormant Projects 73 Fragile X Syndrome - Discontinued Products 74 Fragile X Syndrome - Product Development Milestones 75 Featured News & Press Releases 75 Nov 13, 2014: Marinus Pharmaceuticals Provides Update On Ganaxolone 75 Nov 12, 2014: Neuren's NNZ-2566 successful In Demonstrating Clinical Benefit In Rett syndrome Phase 2 trial 75 Oct 23, 2014: Alcobra Announces Presentation of New Data From Phase III Adult ADHD Study at AACAP Annual Meeting 77 Sep 02, 2014: Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Adolescents With ADHD 79 Aug 19, 2014: Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Fragile X Syndrome 79 Aug 12, 2014: Neuren advances NNZ-2591 towards IND application 79 Aug 08, 2014: Alcobra Releases New Neuroimaging Data Supporting Pro-Cognitive Effects of MDX 80 Jul 14, 2014: Alcobra Completes Patient Recruitment in Phase III Clinical Trial of MDX in Adult ADHD 81 Jun 26, 2014: Neuren completes enrolment in Phase 2 trial of NNZ-2566 in Rett Syndrome 82 May 12, 2014: Alcobra Presents Evidence of Novel Mechanism of Action for Metadoxine Extended Release (MDX) in Cognitive Disorders at the Society of Biological Psychiatry Annual Meeting 82 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 85 Disclaimer 85
List of Tables Number of Products under Development for Fragile X Syndrome, H2 2014 9 Number of Products under Development for Fragile X Syndrome - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Comparative Analysis by Unknown Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Products under Investigation by Universities/Institutes, H2 2014 18 Fragile X Syndrome - Pipeline by Alcobra Ltd, H2 2014 19 Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H2 2014 20 Fragile X Syndrome - Pipeline by Cortex Pharmaceuticals, Inc., H2 2014 21 Fragile X Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 22 Fragile X Syndrome - Pipeline by Hua Medicine Ltd., H2 2014 23 Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals, Inc., H2 2014 24 Fragile X Syndrome - Pipeline by MI.TO. Technology S.r.L., H2 2014 25 Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Limited, H2 2014 26 Fragile X Syndrome - Pipeline by Nexgenix Pharmaceuticals, LLC, H2 2014 27 Fragile X Syndrome - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 28 Fragile X Syndrome - Pipeline by Selvita SA, H2 2014 29 Assessment by Monotherapy Products, H2 2014 30 Number of Products by Stage and Target, H2 2014 32 Number of Products by Stage and Mechanism of Action, H2 2014 34 Number of Products by Stage and Route of Administration, H2 2014 36 Number of Products by Stage and Molecule Type, H2 2014 38 Fragile X Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 62 Fragile X Syndrome - Dormant Projects, H2 2014 73 Fragile X Syndrome - Discontinued Products, H2 2014 74
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.